Caitlyn Jenner Women's HRT: What She Has Said About Her Medication

What Caitlyn Jenner Has Actually Said About Hormone Therapy

Jenner's public statements on HRT are detailed, consistent across multiple media appearances, and clinically informative. She has framed hormone therapy not as cosmetic intervention but as medically necessary care.

The 2015 ABC Interview and "I Am Cait"

In her April 2015 interview with Diane Sawyer on ABC's "20/20," Jenner confirmed she had been taking hormones and described them as part of her transition. The E! Documentary series "I Am Cait," which aired from 2015 to 2016, showed Jenner discussing medication management with her medical team on camera. She referenced estrogen explicitly and described changes in skin texture, emotional experience, and physical appearance as direct effects of her regimen.

She has stated that she began low-dose hormone therapy before her public transition, which aligns with the stepped-care model described in the 2017 Endocrine Society Clinical Practice Guideline, where clinicians initiate therapy at lower doses and titrate based on serum levels and clinical response.

Her Autobiography "The Secrets of My Life" (2017)

Jenner's memoir provided the most detailed account of her medication history available in the public record. She described taking estrogen for years before her public transition and discussed the psychological relief she experienced. She did not name specific brand formulations in terms accessible to general readers, but the clinical context she described, including blood test monitoring and dose adjustments, matches standard feminizing HRT practice outlined in published guidelines [1].

Statements on Aging and HRT

Jenner transitioned publicly at age 65. She has acknowledged in multiple interviews that her age required careful clinical management, particularly around cardiovascular risk. This is consistent with guidance from the Endocrine Society, which notes that older transgender women require individualized risk assessment before and during feminizing HRT, particularly for thromboembolic and cardiovascular events [1].

The Medications Used in Feminizing HRT: Clinical Overview

Standard feminizing HRT for transgender women involves two drug classes: estrogens to produce feminizing effects, and anti-androgens to suppress endogenous testosterone. Jenner has publicly referenced both categories.

Estrogen Formulations

Estradiol is the preferred estrogen in all major guidelines. The 2017 Endocrine Society guideline recommends targeting serum estradiol levels of 100 to 200 pg/mL and suppressing testosterone to below 50 ng/dL [1]. Routes of administration include:

• Oral estradiol: 2 to 6 mg/day. Convenient but associated with higher first-pass hepatic metabolism, which elevates clotting factor production and raises venous thromboembolism (VTE) risk [2].
• Transdermal estradiol patch or gel: 0.05 to 0.2 mg/day. Bypasses hepatic first-pass metabolism, producing lower VTE risk. A 2016 cohort study published in Thrombosis Research (N=695) found transdermal estradiol was associated with significantly lower thrombotic risk compared with oral formulations [2].
• Intramuscular estradiol valerate or cypionate: Used less frequently in outpatient feminizing HRT but produces stable serum levels.

The FDA label for estradiol carries a boxed warning regarding endometrial cancer (in patients with a uterus), cardiovascular events, and breast cancer with extended use [3].

Anti-Androgens

Testosterone suppression is typically achieved with one of three agents:

Spironolactone is the most commonly prescribed anti-androgen in the United States for feminizing HRT. Standard doses range from 100 to 200 mg/day. It acts as an androgen receptor antagonist and also reduces testosterone synthesis. The main monitoring concern is hyperkalemia, particularly in patients with renal impairment [4]. The FDA prescribing information for spironolactone lists hyperkalemia and fluid/electrolyte imbalance as key risks [4].

Bicalutamide is a non-steroidal androgen receptor blocker used off-label at 25 to 50 mg/day. It does not suppress testosterone production but blocks its action at target tissues. A 2019 retrospective study in the Journal of the Endocrine Society (N=76) found bicalutamide effective for testosterone suppression in transgender adolescents and adults with a favorable side-effect profile [5].

GnRH agonists such as leuprolide or histrelin produce near-complete testosterone suppression by downregulating the hypothalamic-pituitary-gonadal axis. They are more expensive and typically reserved for patients who cannot tolerate spironolactone or bicalutamide, or for adolescents requiring puberty suppression [6].

Why Age 65 Matters Clinically: Jenner's Specific Risk Profile

Most published HRT studies in transgender women include younger cohorts. Jenner's public transition at 65 places her in a population with less clinical data and higher baseline cardiovascular risk.

Cardiovascular and Thromboembolic Risk

The University of California San Francisco Transgender Care guidelines note that patients over 60 initiating feminizing HRT require baseline assessment of cardiovascular disease, hypertension, diabetes, and prior VTE history before therapy begins [7]. Oral estradiol in this age group may carry the same elevated clotting risk seen in postmenopausal cisgender women taking oral conjugated equine estrogen, as documented in the Women's Health Initiative (WHI) trial, where conjugated estrogens plus medroxyprogesterone acetate increased VTE risk by approximately 2.1-fold compared with placebo [8].

Transdermal estradiol avoids this problem. A 2015 meta-analysis in Climacteric (14 studies, N over 400,000) found transdermal estradiol carried no statistically significant increase in VTE risk versus no treatment, while oral estradiol doubled that risk [9].

Bone Density Considerations

Estrogen deficiency in any adult accelerates bone loss. Transgender women who suppressed testosterone for extended periods before initiating estrogen therapy may present with reduced baseline bone mineral density. The Endocrine Society recommends baseline DEXA scanning and periodic monitoring in this population [1]. Estradiol preserves bone density through the same mechanism documented in cisgender postmenopausal women, as shown in the HOPE trial (N=333), where estradiol 0.025 mg/day patch prevented bone loss at the spine and hip versus placebo at 2 years [10].

What the Evidence Says About Feminizing HRT Outcomes

Jenner's reported experience, including changes in body fat distribution, skin texture, and emotional regulation, aligns with the documented pharmacological effects of feminizing HRT in the medical literature.

Body Composition and Physical Changes

A 2018 systematic review in Andrology (17 studies) found that feminizing HRT produced measurable reductions in lean body mass and increases in fat mass within 3 to 6 months of initiation, with body fat redistribution toward the hips and thighs continuing for up to 2 years [11]. Breast development typically begins within 3 to 6 months and reaches a plateau at 2 to 3 years, per the 2017 Endocrine Society guideline [1].

Mental Health and Quality of Life

The 2020 systematic review by Dhejne et al. (N=27 studies included) found that gender-affirming hormone therapy was associated with significant improvements in depression, anxiety, and quality-of-life scores across multiple validated instruments [12]. Jenner has spoken openly about emotional improvements she attributed to estrogen, which is consistent with this body of evidence.

Sexual Function

Feminizing HRT reduces libido and changes erectile function in most patients. Jenner discussed this topic publicly in "I Am Cait," describing shifts in sexual experience she attributed to hormone therapy. A 2014 prospective study in Hormones and Behavior (N=96) found testosterone suppression below 50 ng/dL reduced sexual desire scores significantly within 3 months of anti-androgen initiation [13].

How Standard Feminizing HRT Is Monitored

Clinical monitoring prevents the most serious adverse effects. Jenner's statements about receiving regular blood tests align exactly with protocol.

Lab Monitoring Schedule

The 2017 Endocrine Society guideline specifies:

• Serum estradiol and total testosterone: every 3 months in the first year, then every 6 to 12 months once stable [1].
• Serum potassium: every 3 months for patients on spironolactone, particularly in the first year [4].
• Complete metabolic panel and lipid panel: annually.
• Prolactin: baseline and then periodically, since supraphysiologic estradiol levels may stimulate pituitary lactotrophs [1].
• DEXA scan: baseline for patients with risk factors, then every 1 to 2 years [1].

Target Hormone Levels

Per Endocrine Society guidance, the clinical target is:

• Serum estradiol: 100 to 200 pg/mL
• Serum total testosterone: <50 ng/dL

Monitoring labs should be drawn at trough (before the next dose for oral or patch formulations) to avoid overestimating mean exposure [1].

Prescribing Field for Older Adults Starting Feminizing HRT

Fewer than 20% of published transgender HRT cohort studies have included participants over age 60, according to a 2021 review in the Journal of Clinical Endocrinology and Metabolism [14]. This data gap means clinicians managing older patients often extrapolate from both the transgender literature and the postmenopausal cisgender HRT literature simultaneously.

The American Association of Clinical Endocrinology (AACE) recommends individualized shared decision-making for older adults considering feminizing HRT, with explicit documentation of cardiovascular risk stratification before initiation [15].

Jenner's willingness to discuss her age and her medical management publicly has contributed to awareness that age alone is not a contraindication to feminizing HRT, provided appropriate risk assessment is completed. The World Professional Association for Transgender Health (WPATH) Standards of Care, Version 8 state clearly that "there is no upper age limit for gender-affirming hormone therapy" and that eligibility is based on individualized clinical assessment, not chronological age [6].

Informed Consent and the Role of Public Figures in HRT Awareness

Jenner's public statements have occurred in the context of a broader informed-consent model for gender-affirming care. The informed-consent approach, endorsed by UCSF Transgender Care and the WPATH SOC8, removes the requirement for a mental health diagnosis before initiating HRT and places decision-making authority with the patient after a thorough review of risks and benefits [6].

"The informed consent model requires that patients demonstrate an understanding of the risks, benefits, alternatives, unknowns, and limitations of treatment, as well as the consequences of no treatment." That language comes directly from UCSF Transgender Care clinical guidance and represents the standard of care at most major U.S. Gender-affirming health centers [7].

Public figures who describe their own informed-consent conversations, as Jenner has done in interviews and her memoir, may reduce barriers to care for others by normalizing the clinical process. A 2022 survey study in Transgender Health (N=1,216 transgender adults) found that 41% of respondents cited media representation of transgender people as a factor that helped them feel comfortable seeking care [16].

Specific Drug Interactions and Safety Considerations Jenner's Age Raises

Older adults starting feminizing HRT face several drug-interaction risks not prominent in younger cohorts.

Spironolactone and Common Geriatric Medications

Spironolactone interacts with ACE inhibitors, ARBs, and NSAIDs, all common in patients over 60. Co-administration raises potassium further. Patients on lisinopril or losartan should have potassium checked within 2 weeks of spironolactone initiation and then monthly for the first 3 months, per FDA prescribing guidance [4].

Estradiol and Statin Interactions

Oral estradiol may modestly increase triglycerides, which is relevant for patients already on statin therapy. Transdermal estradiol has a neutral-to-favorable lipid profile. A 2017 cross-sectional analysis in Atherosclerosis (N=2,418) found transdermal estradiol was not associated with elevated triglycerides, while oral estradiol produced a mean 15% increase in serum triglycerides [17].

Warfarin and Estrogen

Patients on warfarin who initiate oral estradiol require more frequent INR monitoring. Estrogen's effect on coagulation factors alters warfarin metabolism unpredictably. The FDA label for estradiol lists anticoagulants as a drug class requiring caution [3].